Russell Investments Group Ltd. Has $97.69 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Russell Investments Group Ltd. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 137,208 shares of the biopharmaceutical company’s stock after acquiring an additional 7,944 shares during the quarter. Russell Investments Group Ltd. owned 0.12% of Regeneron Pharmaceuticals worth $97,690,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $802,036,000. Amundi raised its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Loomis Sayles & Co. L P grew its position in Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after acquiring an additional 393,997 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after buying an additional 219,162 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after purchasing an additional 155,369 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $573.45 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a fifty day moving average price of $676.70 and a 200 day moving average price of $779.13. Regeneron Pharmaceuticals, Inc. has a 1 year low of $572.00 and a 1 year high of $1,211.20. The stock has a market cap of $62.69 billion, a PE ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Citigroup cut their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.